Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 47.24 USD 2.65% Market Closed
Market Cap: 4.4B USD
Have any thoughts about
Ultragenyx Pharmaceutical Inc?
Write Note

Intrinsic Value

RARE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RARE stock under the Base Case scenario is 66.1 USD. Compared to the current market price of 47.24 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RARE Intrinsic Value
66.1 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ultragenyx Pharmaceutical Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RARE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RARE?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ultragenyx Pharmaceutical Inc

Provide an overview of the primary business activities
of Ultragenyx Pharmaceutical Inc.

What unique competitive advantages
does Ultragenyx Pharmaceutical Inc hold over its rivals?

What risks and challenges
does Ultragenyx Pharmaceutical Inc face in the near future?

Has there been any significant insider trading activity
in Ultragenyx Pharmaceutical Inc recently?

Summarize the latest earnings call
of Ultragenyx Pharmaceutical Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ultragenyx Pharmaceutical Inc.

Provide P/S
for Ultragenyx Pharmaceutical Inc.

Provide P/E
for Ultragenyx Pharmaceutical Inc.

Provide P/OCF
for Ultragenyx Pharmaceutical Inc.

Provide P/FCFE
for Ultragenyx Pharmaceutical Inc.

Provide P/B
for Ultragenyx Pharmaceutical Inc.

Provide EV/S
for Ultragenyx Pharmaceutical Inc.

Provide EV/GP
for Ultragenyx Pharmaceutical Inc.

Provide EV/EBITDA
for Ultragenyx Pharmaceutical Inc.

Provide EV/EBIT
for Ultragenyx Pharmaceutical Inc.

Provide EV/OCF
for Ultragenyx Pharmaceutical Inc.

Provide EV/FCFF
for Ultragenyx Pharmaceutical Inc.

Provide EV/IC
for Ultragenyx Pharmaceutical Inc.

Show me price targets
for Ultragenyx Pharmaceutical Inc made by professional analysts.

What are the Revenue projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past Revenue estimates
for Ultragenyx Pharmaceutical Inc?

What are the Net Income projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past Net Income estimates
for Ultragenyx Pharmaceutical Inc?

What are the EPS projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past EPS estimates
for Ultragenyx Pharmaceutical Inc?

What are the EBIT projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past EBIT estimates
for Ultragenyx Pharmaceutical Inc?

Compare the revenue forecasts
for Ultragenyx Pharmaceutical Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ultragenyx Pharmaceutical Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ultragenyx Pharmaceutical Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ultragenyx Pharmaceutical Inc compared to its peers.

Compare the P/E ratios
of Ultragenyx Pharmaceutical Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ultragenyx Pharmaceutical Inc with its peers.

Analyze the financial leverage
of Ultragenyx Pharmaceutical Inc compared to its main competitors.

Show all profitability ratios
for Ultragenyx Pharmaceutical Inc.

Provide ROE
for Ultragenyx Pharmaceutical Inc.

Provide ROA
for Ultragenyx Pharmaceutical Inc.

Provide ROIC
for Ultragenyx Pharmaceutical Inc.

Provide ROCE
for Ultragenyx Pharmaceutical Inc.

Provide Gross Margin
for Ultragenyx Pharmaceutical Inc.

Provide Operating Margin
for Ultragenyx Pharmaceutical Inc.

Provide Net Margin
for Ultragenyx Pharmaceutical Inc.

Provide FCF Margin
for Ultragenyx Pharmaceutical Inc.

Show all solvency ratios
for Ultragenyx Pharmaceutical Inc.

Provide D/E Ratio
for Ultragenyx Pharmaceutical Inc.

Provide D/A Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Interest Coverage Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Altman Z-Score Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Quick Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Current Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Cash Ratio
for Ultragenyx Pharmaceutical Inc.

What is the historical Revenue growth
over the last 5 years for Ultragenyx Pharmaceutical Inc?

What is the historical Net Income growth
over the last 5 years for Ultragenyx Pharmaceutical Inc?

What is the current Free Cash Flow
of Ultragenyx Pharmaceutical Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ultragenyx Pharmaceutical Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ultragenyx Pharmaceutical Inc

Current Assets 799.6m
Cash & Short-Term Investments 621.6m
Receivables 93.3m
Other Current Assets 84.7m
Non-Current Assets 738.8m
Long-Term Investments 203.1m
PP&E 272.4m
Intangibles 209.3m
Other Non-Current Assets 53.9m
Current Liabilities 285m
Accounts Payable 36m
Accrued Liabilities 195.5m
Other Current Liabilities 53.6m
Non-Current Liabilities 906.5m
Other Non-Current Liabilities 906.5m
Efficiency

Earnings Waterfall
Ultragenyx Pharmaceutical Inc

Revenue
522.7m USD
Cost of Revenue
-71.9m USD
Gross Profit
450.9m USD
Operating Expenses
-986.6m USD
Operating Income
-535.7m USD
Other Expenses
-23.2m USD
Net Income
-559m USD

Free Cash Flow Analysis
Ultragenyx Pharmaceutical Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Ultragenyx achieved $139 million in total revenue, marking a significant 42% increase from the previous year. The robust performance was led by Crysvita, which generated $98 million. Operating expenses totaled $271 million, resulting in a net loss of $134 million. The company reaffirmed its 2024 total revenue guidance of $530-$550 million, expecting Crysvita sales to reach $375-$400 million. Notably, Ultragenyx is progressing on three late-stage drug applications, aiming for potential approvals soon, which could enhance revenue streams and advance towards profitability by late 2026.

What is Earnings Call?
Fundamental Scores

RARE Profitability Score
Profitability Due Diligence

Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
25/100
Profitability
Score

Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

RARE Solvency Score
Solvency Due Diligence

Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc

Wall Street analysts forecast RARE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RARE is 94.42 USD with a low forecast of 48.48 USD and a high forecast of 147 USD.

Lowest
Price Target
48.48 USD
3% Upside
Average
Price Target
94.42 USD
100% Upside
Highest
Price Target
147 USD
211% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RARE?

Click here to dive deeper.

Dividends

Ultragenyx Pharmaceutical Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RARE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RARE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RARE News

Other Videos

Profile

Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.4B USD

Dividend Yield

0%

Description

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The company is headquartered in Novato, California and currently employs 1,119 full-time employees. The company went IPO on 2014-01-31. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Contact

CALIFORNIA
Novato
60 Leveroni Ct
+14154838800.0
www.ultragenyx.com

IPO

2014-01-31

Employees

1 119

Officers

Founder, President, CEO & Director
Dr. Emil D. Kakkis M.D., Ph.D.
Executive VP of Corporate Strategy & CFO
Mr. Howard Horn
Chief Legal Officer & Executive VP of Corporate Affairs
Ms. Karah Herdman Parschauer J.D.
Chief Quality Operations Officer & Executive VP of Translational Sciences
Mr. John Richard Pinion II
Executive VP & Chief Commercial Officer
Mr. Erik Harris M.B.A.
Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Theodore A. Huizenga
Show More
Chief Human Resources Officer & Executive VP
Mr. Ernie W. Meyer
Chief Business Officer & Executive VP
Mr. Thomas R. Kassberg
Senior Vice President of Business Development & Alliance Management
Mr. Vimal Srivastava
Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development
Mr. Dennis Karl Huang
Show Less

See Also

Discover More
What is the Intrinsic Value of one RARE stock?

The intrinsic value of one RARE stock under the Base Case scenario is 66.1 USD.

Is RARE stock undervalued or overvalued?

Compared to the current market price of 47.24 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 29%.

Back to Top